Welcome to our dedicated page for GSK plc SEC filings (Ticker: GLAXF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GSK PLC (GLAXF) filings document foreign-issuer disclosures for a global biopharma company registered in England and Wales. The record centers on Form 6-K current reports furnished under the Exchange Act, including announcements on product collaborations, capital-return programs, annual general meeting voting results, remuneration matters, board elections, and transaction notifications involving American Depositary Shares.
The filings also describe GSK's securities framework, including ordinary shares and ADS instruments, share repurchases and treasury-share treatment, PDMR transaction reporting, and governance resolutions connected with annual reporting and shareholder approvals. Product-related reports identify bepirovirsen in chronic hepatitis B and outline regulatory, quality, pharmacovigilance, commercial access, and global medical-strategy responsibilities associated with collaboration arrangements.
GSK plc reports that on 13 March 2026 it repurchased 445,000 ordinary shares of 31¼ pence each through BNP Paribas under its existing share buyback programme. Prices ranged from 2,027.00p to 2,060.00p per share, with a volume‑weighted average price of 2,041.70p.
The shares bought will be held as treasury shares. Since 17 February 2026, GSK has repurchased 9,925,409 ordinary shares. After this transaction, it holds 249,816,503 shares in treasury and has 4,066,354,262 ordinary shares in issue and voting rights, with treasury shares representing 6.14% of voting rights.
GSK plc reports that the US FDA has expanded the approved age indication for its RSV vaccine Arexvy to adults aged 18 to 49 years who are at increased risk for lower respiratory tract disease caused by RSV. Arexvy was previously approved in the US for adults 60 and older, and for adults 50-59 at increased risk. GSK notes that an estimated 21 million US adults under 50 have at least one risk factor for severe RSV infection, and that RSV drives about 17,000 hospitalisations and 1.97 million outpatient visits annually among adults 18-49 years. The label expansion is supported by a Phase IIIb trial showing a non-inferior immune response versus adults 60 and above, with a safety profile consistent with earlier Phase III data.
GSK plc reports that, on 12 March 2026, it repurchased 790,000 ordinary shares of 31¼ pence each through BNP Paribas under its existing share buyback programme. Prices ranged from 2,016.00p to 2,057.00p per share, with a volume‑weighted average price of 2,036.73p.
The repurchased shares will be held as treasury shares. Since 17 February 2026, GSK has bought back a total of 9,480,409 ordinary shares. Following this latest transaction, the company holds 249,371,503 shares in treasury and has 4,066,797,319 ordinary shares in issue, giving a total of 4,066,797,319 voting rights.
GSK states that, in line with DTR 5.5.1R, 6.13 per cent of its voting rights are now attributable to ordinary shares held in treasury.
GSK plc reported that several senior leaders acquired small amounts of equity through company share plans. On March 10, 2026, executives including the President, Europe; Chief Financial Officer; Group General Counsel; President, Corporate Development; President, Global Supply Chain; President, Global Affairs; CEO, ViiV Healthcare and President, Global Health; and the SVP & Company Secretary each acquired 12 Ordinary Shares of 31¼ pence at £20.7168 per share under GSK's Share Reward Plan on the London Stock Exchange.
In a separate transaction on March 9, 2026, President Maya Martinez-Davis acquired 2.150 notional American Depositary Shares at $55.5100 within her GSK Executive Supplemental Savings Plan account on the New York Stock Exchange.
GSK plc reports that on 11 March 2026 it repurchased 513,409 ordinary shares of 31¼ pence each through BNP Paribas under its existing share buyback programme. The shares were bought between 2,047.00p and 2,078.00p at a volume-weighted average price of 2,061.69p and will be held as treasury shares.
Since 17 February 2026, GSK has repurchased 8,690,409 shares. After this transaction, it holds 248,581,503 shares in treasury and has 4,067,587,319 ordinary shares in issue, which is also the total number of voting rights. Treasury shares represent 6.11% of voting rights.
GSK plc reports that, acting through BNP Paribas, it repurchased 505,000 ordinary shares of 31¼ pence each on 10 March 2026. The shares were bought at prices between 2,052.00p and 2,082.00p, with a volume-weighted average price of 2,066.69p per share.
The repurchased shares will be held as treasury shares as part of GSK’s existing share buyback programme under a non-discretionary agreement with the broker announced on 17 February 2026. Since that date, GSK has bought 8,177,000 shares in total under the programme.
After this transaction, GSK holds 248,068,094 shares in treasury and has 4,068,100,728 ordinary shares in issue, giving a total of 4,068,100,728 voting rights. The company confirms that treasury shares represent 6.10 per cent of its voting rights.
GSK plc reports that it bought back 516,000 of its ordinary shares on 9 March 2026 through BNP Paribas SA under its existing non-discretionary share buyback programme. The volume-weighted average price was 2,028.51p per share, within a range of 1,989.00p to 2,047.00p.
The shares purchased will be held as treasury shares. Since 17 February 2026, GSK has bought 7,672,000 ordinary shares under this programme. After this transaction, it holds 247,563,094 shares in treasury and has 4,068,605,728 ordinary shares in issue, which equals 4,068,605,728 voting rights.
GSK confirms that, following these purchases, the percentage of voting rights attributable to treasury shares is 6.08%, a figure shareholders may use when assessing notification thresholds under the UK Financial Conduct Authority’s disclosure and transparency rules.
GSK plc reported a change in its Board committee membership. Effective 9 March 2026, Elizabeth McKee Anderson has been appointed as a member of the Corporate Responsibility Committee. She will serve on this committee in addition to her existing roles on the Audit & Risk and Remuneration committees.
GSK plc has signed a licence agreement granting Alfasigma worldwide exclusive rights to develop, manufacture and commercialise linerixibat, an investigational IBAT inhibitor for cholestatic pruritus in primary biliary cholangitis (PBC).
GSK will receive an upfront payment of $300 million, plus $100 million upon US FDA approval, $20 million upon EU and UK approvals, and up to $270 million in sales-based milestones, along with tiered double-digit royalties on global net sales. Linerixibat has positive phase III GLISTEN data and is under regulatory review in several major markets but is not yet approved anywhere. The transaction remains subject to customary conditions, including regulatory clearances such as under the US Hart-Scott-Rodino Act.
GSK plc reports it repurchased 690,000 ordinary shares of 31¼ pence each on 06 March 2026 through BNP Paribas under its existing share buyback programme. The lowest price paid was 2,029.00p, the highest was 2,080.00p, and the volume‑weighted average price was 2,048.95p per share.
The purchased shares will be held as treasury shares. Since 17 February 2026, GSK has bought 7,156,000 ordinary shares. After this transaction, it holds 247,047,094 shares in treasury and has 4,069,121,728 ordinary shares in issue, which is also the total number of voting rights.
The company states that, in line with DTR 5.5.1R, treasury shares represent 6.07% of voting rights. The filing also provides a detailed schedule of purchases by trading venue and individual trades on the London Stock Exchange and CBOE Europe order books.